Chronic myeloid leukemia (CML) is a stem cell hematological disease characterized at the molecular level by the expression of the BCR-ABL1 chimeric oncogenic tyrosine kinase. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.